News

Actoverco Pharmaceutical Company

Selected News

4R4A5641-1-2048x1365

Actover Pharmaceutical Group Participates in the 10th IRAN PHARMA Exhibition

4R4A3136-2048x1365 (1)

Actoverco Medical Director Stated: A Strong Commitment to the “Pharmacovigilance” System Ensures the Safety and Reliability of Actover Products

M_HA18361-2048x1365

Actover Group Unveils “Zeponim” for the Management of Multiple Sclerosis and Ulcerative Colitis

nexus23

Nexus CEO Calls for Equal Market Opportunities for Domestic Supplements at Iran Supplex 2025

4R4A0525

Actover Pharmaceutical Group Showcases Its Neurology Portfolio at the 32nd Iranian Congress of Neurology and Clinical Electrophysiology

Official opening of the new factory for production of Actoverco solid drugs (Actoverco 2)

According to PHANA, the official opening and operation ceremony of the new Actoverco solid drug production factory was held in Baharestan Industrial Town.

Actoverco’s CEO resigned

According to Actoverco’s Public Relations, Shahram Shini, CEO of Actoverco, has recently resigned.

Another big step of Iran in the production of anti-cancer drugs

The largest factory for the production of anti-cancer drugs in the Middle East, as well as the biotechnology department of the pharmaceutical group, was put into operation in Alborz with the presence of the Minister of Health.

Nahaleh Naraghi irán pharma

Actoverco received 90.8 million Euros of governmental currency in the first half of this year

The CEO of Actoverco said: “This Company has received about 90 million and 800 thousand Euros of governmental currency in the first 6 months of the year.”

We do not talk, we act

Shini, CEO of Actoverco on the sidelines of ICCU 2018 in a conversation with PHANA: With proper planning, none of the Actoverco’s drugs will not experience a shortage. We have…

nahaleh naraghi ceo of actoverco

With the lifting of sanctions, many announced their readiness to work with “Actoverco

We have a program for production of Rituximab and Bevacizumab drugs for cancer patients, ophthalmologists, etc. These drugs are very expensive due to their high technical knowledge, and from next year, we will also produce the raw materials for these drugs ourselves.